低分子肽/核酸衍生物/氨基酸/糖脂等与糖代谢  

Actovegin and glycometabolism

作　　者：张玉梅[1] 钱燕宁[1] 

机构地区：[1]南京医科大学第一附属医院麻醉科,江苏南京210029

出　　处：《医学研究生学报》2007年第9期978-981,共4页Journal of Medical Postgraduates

基　　金：国家自然科学基金资助项目(批准号:30672523)

摘　　要：低分子肽/核酸衍生物/氨基酸/糖脂(LNAG,商品名:爱维治)是一种改善细胞能量代谢的药物,主要表现为改善糖的代谢。因它具有胰岛素样活性、能促进葡萄糖的摄取、增强了葡萄糖代谢酶的活性、抑制乳酸合成等作用。LNAG最初主要用于老年性痴呆的治疗,近年来其适应证在不断扩大。Actovegin is a drug, which can improve cellular energy metabolism, especially glycometabolism. It has an insulin-like effect, such as increasing the uptake of glucose and activating glucose metabolic enzyme. In addition, it can inhibit the production of lactic acid. Actovegin was mainly applied to the treatment of Alzheimer disease initially, but now it is indicated more and more.

关 键 词：低分子肽/核酸衍生物/氨基酸/糖脂等 糖代谢 

分 类 号：R961[医药卫生—药理学]